Premium
Human papillomavirus genotype distribution among French women with and without cervical abnormalities
Author(s) -
Casalegno JeanSebastien,
Benchaib Mehdi,
Le Bail Carval Karine,
Piaton Eric,
Mathevet Patrice,
Mekki Yahia
Publication year - 2011
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2011.01.030
Subject(s) - medicine , papanicolaou stain , genotype , cytology , gynecology , human papillomavirus , hpv infection , population , papanicolaou test , cervical cancer , outpatient clinic , obstetrics , cancer , pathology , gene , genetics , biology , environmental health
Objective To assess human papillomavirus (HPV) prevalence and distribution among French women with normal and pathologic cytology findings. Methods A genomic DNA microarray assay enabling the detection of 35 different HPV genotypes was used for in vitro diagnosis, as a complement to Papanicolaou screening, to test 785 women who attended the gynecology department of a hospital in Lyon, France. Results Pathologic and normal cytology findings were obtained for 260 (33.1%) and 302 (38.5%) of the 785 women, respectively, whereas 223 (28.4%) results were inconclusive. HPV infection and multiple infection were significantly more prevalent ( P < 0.001) in the population with pathologic findings (90.0% and 41.9%, respectively) than in the population with normal cytology findings (48.3% and 20.2%, respectively). Overall, the 4 most frequent HPV genotypes were HPV‐16 (14.8%), HPV‐53 (9.0%), HPV‐31 (8.7%), and HPV‐51 (7.5%), whereas HPV‐18 (3.8%), HPV‐6 (2.9%), and HPV‐11 (0.4%) were less common. The HPV genotypes included in the quadrivalent vaccination had a prevalence of 20.6% among all women and 30.4% among those with pathologic findings. Conclusion The present data indicate a reduced direct impact of HPV vaccination in the study population owing to a low prevalence of HPV‐18 and a high prevalence of HPV‐53, HPV‐31, and HPV‐51.